SPR imaging biosensor for the 20S proteasome: Sensor development and application to measurement of proteasomes in human blood plasma

Microchimica Acta

Volumn 175, Issue 1-2, 2011, Pages 177-184

  Gorodkiewicz, Ewa ^a   Ostrowska, Halina ^b   Sankiewicz, Anna ^a  

^a UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

20S proteasome; Biosensor; Epoxomicin; Plasma; PSI; SPRI

Indexed keywords

EID: 80053121731     PISSN: 00263672     EISSN: 14365073     Source Type: Journal    
DOI: 10.1007/s00604-011-0656-6     Document Type: Article

References (40)

1. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801-847.
2. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
3. Baumeister W, Dahlmann B, Hergel R, Kopp F, Kuehn L, Pfeifer G (1988) Electron microscopy and image analysis of the multicatalytic proteinase. FEBS Lett 241: 239-245.
4. Groll M, Dietzel L, Lowe J, Stock D, Bochtler M, Bartnik H, Huber R (1997) Structure of 20S proteasome from yeast at 2, 4 Å resolution. Nature 386: 463-471.
5. Groll M, Bochtler M, Brandstetter H, Clausen T, Huber R (2005) Molecular machines for protein degradation. Chem Bio Chem 6: 222-256.
6. Orlowski M, Wilk S (2000) Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383: 1-16.
7. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758.
8. Groll M, Huber R (2004) Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695: 33-44.
9. de Bettignies G, Coux O (2010) Proteasome inhibitors: dozens of molecules and still counting. Biochimie 92(11): 1530-1545.
10. Myung J, Kim KB, Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21(4): 245-273.
11. Adams J, Kauffman M (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Canc Investig 22: 304-311.
12. Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807.
13. Voorhees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46: 189-213.
14. Crawford LJ, Walker B, Irvine AE (2008) Proteasome inhibitors: a therapeutic strategy for hematological malignancy. Front Biosci 13: 4285-4296.
15. Sixt SU, Dahlmann B (2008) Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta 1782(12): 817-823.
16. Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A (1993) Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 121: 215-223.
17. Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF, Bureau JP (2001) Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 92: 2493-2500.
18. Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, Bureau JP, Ouali A (2002) Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Meth 260: 183-193.
19. Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP, Meunier L (2005) High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 152: 948-953.
20. Jakob C, Egerer K, Liebisch P, Türkmen S, Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner C, Sterz J, Kleeberg L, Feist E, Burmester GR, Kloetzel PM, Sezer O (2007) Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 109: 2100-2103.
21. Henry L, Lavabre-Bertrand T, Vercambre L, Ramos J, Carillo S, Guiraud I, Pouderoux P, Bismuth M, Valats JC, Demattei C, Duny Y, Chaze I, Funakoshi N, Bureau JP, Daurès JP, Blanc P (2009) Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 58: 833-838.
22. Henry L, Lavabre-Bertrand T, Douche T, Uttenweiler-Joseph S, Fabbro-Peray P, Monsarrat B, Martinez J, Meunier L, Stoebner PE (2010) Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma. Exp Dermatol 19: 1054-1059.
23. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, Wohlschlaeger J, Sixt SU (2011) The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol 120: 233-238.
24. Ostrowska H, Hempel D, Holub M, Sokolowski J, Kloczko J (2008) Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem 41: 1377-1383.
25. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M (2008) Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 112: 1306-1312.
26. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M (2009) Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Canc Res 15: 3820-3826.
27. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M (2011) Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res 35: 526-533.
28. Fernández-González A, Rychlowska J, Badía R, Salzer R (2007) SPR imaging as a tool for detecting mucin - anti-mucin interaction. Outline of the development of a sensor for near-patient testing for mucin. Microchim Acta 158: 219-225.
29. Chen H, Lee J, Jo WS, Jeong MH, Koh K (2011) Development of surface plasmon resonance immunosensor for the novel protein immunostimulating factor. Microchim Acta 172: 171-176.
30. Lee HJ, Yan Y, Marriott G, Corn RM (2005) Quantitative functional analysis of protein complexes on surfaces. J Physiol 563: 61-71.
31. Lee HJ, Nedelkov D, Corn RM (2006) Surface Plasmon Resonance Imaging measurements of antibody arrays for the multiplexed detection of low molecular weight protein biomarkers. Anal Chem 78: 6504-6510.
32. Fang S, Lee J, Wark AW, Corn RM (2006) Attomole microarray detection of microRNAs by nanoparticle-amplified SPR Imaging measurements of surface polyadenylation reactions. J Am Chem Soc 128: 14044-14046.
33. Gorodkiewicz E (2007) The Surface Plasmon Resonance Imaging sensor for papain based on immobilized cystatin. Protein Pept Lett 14: 443-445.
34. Gorodkiewicz E (2009) Surface Plasmon Resonance Imaging sensor for cathepsin determination based on immobilized cystatin. Protein Pept Lett 16: 1379-1385.
35. Gorodkiewicz E, Regulska E, Roszkowska-Jakimiec W (2010) Determination of the active form concentration of cathepsins D and B by SPRI biosensors. J Lab Diagn 46: 107-109.
36. Gorodkiewicz E, Regulska E (2010) SPR imaging biosensor for aspartyl cathepsins: sensor development and application for biological material. Protein Pept Let 17: 1148-1154.
37. Gorodkiewicz E, Regulska E, Wojtulewski K (2011) Development of an SPR imaging biosensor for determination of cathepsin G in saliva and white blood cells. Microchim Acta 173: 407-413.
38. Wilk S, Fiqueiredo-Pereira ME (1993) Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein 47: 306-313.
39. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci USA 96: 10406-10408.
40. Egerer K, Kuckelkorn U, Rudolph PE, Rückert JC, Dörner T, Burmester GR, Kloetzel PM, Feist E (2002) Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29(10): 2045-2052.